Retatrutide: Research Evidence and Regulatory Status

Last evidence review: August 27, 2026

Retatrutide, also known by the development code LY3437943, is a synthetic peptide designed to activate three receptor systems: GIP, GLP-1, and glucagon receptors. Its published evidence base includes receptor assays, animal experiments, early clinical studies, phase 2 trials, and a published phase 3 trial.

Retatrutide nevertheless remains investigational in the United States. FDA states that it is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.[1]

This page separates laboratory, animal, and human evidence. It is not medical advice, does not provide use instructions, and does not establish that any catalog material is retatrutide, an approved drug, clinically equivalent to a studied product, or suitable for human use.

Identity at a glance

A UNII is a substance identifier. It is not an approval, quality determination, or statement that a commercial sample matches the identified substance.

“GLP-3” is used by some commercial catalogs, but it is not the accepted name in the FDA substance record or cited primary papers. No Serum Research product should be connected to this page until the product’s exact molecular identity is documented.

The mass statement needs a defined subject

Even after a substance is named, the basis of an amount needs to be explicit. A technical reviewer should ask whether the statement represents nominal fill, measured peptide content, or another reporting convention; whether counterions and water are accounted for; and whether other formulation components are present. These are proposed analytical review questions. This review did not obtain the lot-specific records needed to answer them for GLP-3.

It would therefore be incorrect to infer a salt form, counterion, peptide-equivalent conversion or actual measured content from the product title. This article supplies no such conversion. A printed number is not evidence for the details needed to perform one.

A purity statement cannot, by itself, establish the amount of the intended molecule in a container. A reviewer needs the actual measurement definition, reference material, analytical method and lot linkage. Likewise, an image of a certificate cannot show whether the submitted test sample represents every distributed vial. These are limits on what a document can establish, not findings that any particular certificate is false.

Why it is called a triple-receptor agonist

The discovery program reported agonist activity at the glucose-dependent insulinotropic polypeptide receptor, glucagon-like peptide-1 receptor, and glucagon receptor in its experimental systems.[2] “Triple-receptor agonist” describes that pharmacology. It does not by itself establish a clinical outcome, approval status, or the identity and quality of material sold under an informal catalog name.

Laboratory evidence

The 2022 discovery paper reported receptor-signaling and functional assays used to characterize retatrutide across the three named receptors.[2] These assays help define the intended molecular design and generate hypotheses about downstream biology.

Laboratory receptor activity is mechanistic evidence. It does not establish safety, effectiveness, exposure, or long-term outcomes in people.

Animal evidence

The same discovery program included experiments in mouse models and reported changes in metabolic measurements, food intake, energy expenditure, and body weight under the conditions studied.[2]

Animal models can help researchers decide whether a compound warrants further study. Differences in physiology, experimental exposure, endpoints, and study conditions mean that animal results cannot be treated as human outcomes.

Human clinical research

Early clinical studies

Phase 1 and 1b studies evaluated short-term safety, tolerability, pharmacokinetics, and pharmacodynamic measures.[2][3] Their role was to inform later development. Small, short studies cannot establish a long-term benefit-risk profile.

Phase 2 studies

Randomized phase 2 studies evaluated retatrutide in defined populations with obesity or overweight and with type 2 diabetes.[4][5] A selected MRI substudy assessed liver-fat change as an imaging endpoint.[6]

These findings apply to the studied protocols, populations, formulations, follow-up periods, and endpoints. An imaging endpoint is not the same as a tissue diagnosis or a patient-centered clinical outcome.

Phase 3 program

TRANSCEND-T2D-1 was a 40-week randomized, placebo-controlled phase 3 trial in adults with type 2 diabetes inadequately controlled with diet and exercise; the study was published in 2026.[7] ClinicalTrials.gov lists the trial as completed and, as of this review, does not show posted registry results.

The TRIUMPH-1 registration also remained without posted structured results, while its phase 3 publication was now indexed. The two sources reported different enrollment counts. A responsible summary preserves that unresolved difference instead of silently rewriting one source to match the other.

A phase 3 publication or completed registry record is not FDA approval. Approval requires FDA action on a specific application for a specific product and labeling.

FDA status

FDA’s current page on unapproved GLP-1 products states that retatrutide cannot be used in compounding under federal law and is not a component of an FDA-approved drug.[1] A clinical-trial phase, publication, CAS number, or UNII does not alter that status.

Important evidence limits

• The clinical program does not validate products marketed by third parties as retatrutide, “Reta,” or “GLP-3.”
• A name or labeled vial amount does not establish identity, purity, quantitative content, stability, sterility, or bioavailability.
• Trial findings do not establish outcomes for unstudied populations, combinations, or exposure periods.
• Sponsor-funded studies should be identified as such and evaluated on their design, reporting, and replication.
• Registered studies without posted results do not support a positive-result claim.

Frequently asked questions

Is retatrutide FDA approved?

No. FDA states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.[1]

What is LY3437943?

LY3437943 is the development code used for retatrutide in primary papers and clinical-trial records.

What does triple-receptor agonist mean?

It refers to the reported agonist activity of retatrutide at GIP, GLP-1, and glucagon receptors. It is a pharmacology description, not a guarantee of a clinical result or a product-quality claim.

Does a completed phase 3 trial mean approval?

No. Drug development and FDA approval are separate processes. A completed trial can contribute evidence to a regulatory application, but only FDA approval of that application establishes an approved product and label.

Is “GLP-3” the scientific name for retatrutide?

No. Retatrutide is the accepted name in the cited FDA identity source and primary literature; LY3437943 is its development code. A product described only as “GLP-3” needs an exact identity record before it can be associated with retatrutide.

Primary sources

1. FDA’s concerns with unapproved GLP-1 drugs
2. Discovery and preclinical program, PMID 35985340
3. Phase 1b study, PMID 36354040
4. Phase 2 obesity trial, PMID 37366315
5. Phase 2 type 2 diabetes trial, PMID 37385280
6. MRI liver-fat substudy, PMID 38858523
7. TRANSCEND-T2D-1 publication, PMID 42250575 and trial record NCT06354660
8. TRIUMPH-1 trial record NCT05929066